Multidrug-resistant Gram-negative 'superbugs'are causing a global health crisis. Due to a marked decline in the discovery of antibiotics and the current shortage of new antibiotics, clinicians are often left with little option but to use the polymyxins (polymyxin B and colistin, i.e. polymyxin E). Polymyxins first came onto the market more than 50 years ago and have been used rarely, until recent times. Unfortunately, there is mounting evidence that resistance to polymyxins is increasing. A major factor promoting resistance is that plasma concentrations of polymyxins at recommended daily doses are sub-optimal in a significant proportion of critically-ill patients. Unfortunately, simply increasing th polymyxin daily dose is not an option because kidney toxicity (up to 60% incidence with current regimens) is the major dose-limiting adverse effect. Emergence of resistance to polymyxins is a significant risk with monotherapy and, because of the 'last-line'status, implies resistance to all current antibiotics. This highlights the urgent need to explore novel, highly active dosing strategies with polymyxin combinations. The central aim of the present project is to evaluate novel dosing regimens for polymyxin combinations to maximize antibacterial activity and minimize emergence of resistance and toxicity. Our research strategy involves a systematic evaluation of the effectiveness of novel 'burst', 'front-loading'(e.g. high dose, short duration dosing at the beginning of therapy) and 'sequential'polymyxin combination dosing strategies. The research plan incorporates a multi-tiered approach across a range of in vitro and rabbit infection models. First, in vitro models will be used to simulate the conditions of infection and drug concentration-time profiles in the human body to devise combination dosing strategies that most effectively kill both polymyxin-susceptible and polymyxin-resistant bacteria. Next, promising dosing strategies for the polymyxin combinations will be tested for resistance suppression against clinical isolates in a hollow-fiber infection model. Cutting-edge genomics/transcriptomics/metabolomics studies will guide selection of optimal regimens by characterizing the global bacterial responses (including emergence of resistance) to the novel combination dosing strategies. Finally, prospective validation studies for our superior regimens will be conducted in 10-day immune-compromised and -competent rabbit infection models for prospective evaluation of resistance suppression and toxicity. Each progressive stage will provide key information to uniquely inform the development of innovative mechanism-based mathematical models that will be used to translate across all experimental tiers. The final translation will be performed by mechanism-based Monte Carlo Simulations to propose novel dosing strategies for polymyxin combinations that maximize antibacterial activity and minimize resistance and toxicity for future testing in humans.
Gram-negative 'superbugs'resistant to all current antibiotics except the polymyxins are presenting a global health crisis. As highlighted in the 'Bad Bugs, No Drugs'paper by the Infectious Diseases Society of America, no new antibiotics will be available for these pathogens for many years to come. This highlights the significance of the current project which aims to preserve the usefulness of polymyxins through the study of novel dosing strategies for polymyxin combinations which optimally suppress resistance emergence and minimize nephrotoxicity against the Gram-negative 'superbugs'
|Garonzik, Samira M; Lenhard, Justin R; Forrest, Alan et al. (2016) Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach. PLoS One 11:e0156131|
|Tran, Thien B; Velkov, Tony; Nation, Roger L et al. (2016) Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents 48:592-597|
|Ly, Neang S; Bulman, Zackery P; Bulitta, JÃ¼rgen B et al. (2016) Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa. Antimicrob Agents Chemother 60:2870-80|
|Cheah, Soon-Ee; Johnson, Matthew D; Zhu, Yan et al. (2016) Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens. Sci Rep 6:26233|
|Tsuji, Brian T; Landersdorfer, Cornelia B; Lenhard, Justin R et al. (2016) Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 60:3913-20|
|Li, Chen; Ching Han Chang, Catherine; Nagel, Jeremy et al. (2016) Critical evaluation of in silico methods for prediction of coiled-coil domains in proteins. Brief Bioinform 17:270-82|
|Lenhard, Justin R; Brown, Tanya; Rybak, Michael J et al. (2015) Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. Antimicrob Agents Chemother 60:1584-91|
|Bergen, Phillip J; Bulman, Zackery P; Saju, Sarith et al. (2015) Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy 35:34-42|
|Bulman, Zackery P; Sutton, Mark D; Ly, Neang S et al. (2015) Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutators. Antimicrob Agents Chemother 59:4343-6|
|Bergen, Phillip J; Bulman, Zackery P; Landersdorfer, Cornelia B et al. (2015) Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infect Dis Ther 4:391-415|
Showing the most recent 10 out of 11 publications